148356-79-0

Basic information

• Product Name: methyl 5-chloro-1-methyl-1H-indole-2-carboxylate
• Synonyms: methyl 5-chloro-1-methyl-1H-indole-2-carboxylate;5-chloro-1-methyl-2-indolecarboxylic acid methyl ester;5-chloro-1-methyl-indole-2-carboxylic acid methyl ester;methyl 5-chloro-1-methyl-indole-2-carboxylate;methyl 5-chloro-1-methylindole-2-carboxylate
• CAS NO: 148356-79-0
• Molecular Formula: C₁₁H₁₀ClNO₂
• Molecular Weight: 223.6556
• Mol File: 148356-79-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: methyl 5-chloro-1-methyl-1H-indole-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 5-chloro-1-methyl-1H-indole-2-carboxylate(148356-79-0)
• EPA Substance Registry System: methyl 5-chloro-1-methyl-1H-indole-2-carboxylate(148356-79-0)

Safety Data

• Hazardous Substances Data: 148356-79-0(Hazardous Substances Data)

Upstream product

• 587-04-2 m-Chlorobenzaldehyde 
• 10517-21-2 5-chloro-1H-Indole-2-carboxylic acid 
• 74-88-4 methyl iodide 
• 87802-11-7 methyl 5-chloroindole-2-carboxylate 

Downstream Products

• 59908-47-3 5-chloro-1-methyl-1H-indole-2-carboxylic acid 
• 883529-71-3 5-chloro-1-methyl-1H-indole-2-carbaldehyde 

Relevant articles and documents

Intracellular Trapping of the Selective Phosphoglycerate Dehydrogenase (PHGDH) Inhibitor BI-4924 Disrupts Serine Biosynthesis

Phosphoglycerate dehydrogenase (PHGDH) is known to be the rate-limiting enzyme in the serine synthesis pathway in humans. It converts glycolysis-derived 3-phosphoglycerate to 3-phosphopyruvate in a co-factor-dependent oxidation reaction. Herein, we report the discovery of BI-4916, a prodrug of the co-factor nicotinamide adenine dinucleotide (NADH/NAD+)-competitive PHGDH inhibitor BI-4924, which has shown high selectivity against the majority of other dehydrogenase targets. Starting with a fragment-based screening, a subsequent hit optimization using structure-based drug design was conducted to deliver a single-digit nanomolar lead series and to improve potency by 6 orders of magnitude. To this end, an intracellular ester cleavage mechanism of the ester prodrug was utilized to achieve intracellular enrichment of the actual carboxylic acid based drug and thus overcome high cytosolic levels of the competitive cofactors NADH/NAD+

Flexibility of small molecular CD4 mimics as HIV entry inhibitors

CD4 mimics such as YIR-821 and its derivatives are small molecules which inhibit the interaction between the Phe43 cavity of HIV-1 gp120 with host CD4, an interaction that is involved in the entry of HIV to cells. Known CD4 mimics generally possess three

N-(piperidin-4-yl)-1H-indole-2-carboxamide derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating Urotensin-Ⅱ receptor activity related diseases containing the same as an active ingredient

The present invention relates to N-(piperidin-4-yl)-1H-indole-2-carboxamide derivatives, a preparation method thereof, and a pharmaceutical composition for preventing or treating urotensin-II receptor activity-related diseases comprising the same as activ

Pharmacokinetics and Metabolism of Selective Oxoeicosanoid (OXE) Receptor Antagonists and Their Effects on 5-Oxo-6,8,11,14-eicosatetraenoic Acid (5-Oxo-ETE)-Induced Granulocyte Activation in Monkeys

The potent eosinophil chemoattractant 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) is a 5-lipoxygenase product that acts via the selective OXE receptor, which is present in many species, but not rodents. We previously reported that the indole 230 is

3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions and methods useful for treating a variety of diseases, disorders or conditions, associated with PHGDH.

Enantioselective organocatalytic intramolecular ring-closing Friedel-Crafts-type alkylation of indoles

An enantioselective organocatalytic intramolecular ring-closing Friedel-Crafts-type alkylation of indolyl α,β-unsaturated aldehydes has been developed. This powerful new strategy allows enantioselective access to THPIs and THBCs in a straightforward and a

COMPOUNDS THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE KV FAMILY

The present invention relates to compounds that interact with ion channels. In particular, the invention relates to compounds having the structural Formula (I), (II), (III) or (IV), stereoisomers, tautomers, racemics, prodrugs, metabolites thereof, or a pharmaceutically acceptable salt and/or solvate thereof, Formula (I), (II), (III), (IV), wherein X1, X2, Y, Z, W, R1, R8 , R9, R10, L, A, z, and n have the meaning defined in claim 1. The invention also relates to methods for preparing said compounds, to pharmaceutical compositions comprising said compounds, and to the use of said compounds in methods for treatment of the human and animal body.